Drugmakers: Commercial Franchises & Pipeline Renewal

Own commercial drug manufacturers whose established medicines fund the next wave of patent-protected products, rather than research tools, speculative discovery platforms or a single treatment category. The opportunity is franchise renewal through approvals, new indications and pipeline execution across distinct therapeutic markets. Recent strength in several manufacturers makes this a timely, diversified healthcare allocation, while patent expirations, trial failures and reimbursement pressure remain the central risks. Launch basket (equal weight): ABBV, MRK, AMGN, LLY, MRNA, BMY, GILD, PFE Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.